Sensitivity to Intravenous Nicotine: Genetic Moderators
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the
subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The
subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including
the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG
genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV
nicotine when compared to those with AA genotype.